Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.
This report contains market size and forecasts of Late Stage Chronic Kidney Disease Drugs in Global, including the following market information:
Global Late Stage Chronic Kidney Disease Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Late Stage Chronic Kidney Disease Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Calcimimetics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Late Stage Chronic Kidney Disease Drugs include AbbVie, Amgen, Ardelyx, AstraZeneca, Deltanoid, Akebia Therapeutics, Kyowa Hakko Kirin, OPKO Health and Vifor Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Late Stage Chronic Kidney Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Late Stage Chronic Kidney Disease Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Late Stage Chronic Kidney Disease Drugs Market Segment Percentages, by Type, 2021 (%)
Calcimimetics
Vitamin D Sterols
Potassium Binders
Others
Global Late Stage Chronic Kidney Disease Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Late Stage Chronic Kidney Disease Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies
Global Late Stage Chronic Kidney Disease Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Late Stage Chronic Kidney Disease Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Late Stage Chronic Kidney Disease Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Late Stage Chronic Kidney Disease Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Amgen
Ardelyx
AstraZeneca
Deltanoid
Akebia Therapeutics
Kyowa Hakko Kirin
OPKO Health
Vifor Pharma
Sanofi
Shield Therapeutics
Shire
Spectrum
ZS Pharma